Skip to main content

Anastrozole-Induced Bone Loss

Meaning

Anastrozole-Induced Bone Loss is a significant clinical complication characterized by an accelerated reduction in bone mineral density (BMD) in postmenopausal women receiving anastrozole therapy for estrogen receptor-positive breast cancer. This adverse effect significantly elevates the patient’s susceptibility to fragility fractures, particularly those affecting the spine and hip. The resulting skeletal fragility necessitates careful monitoring and prophylactic intervention to maintain structural integrity and reduce morbidity.